These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 34353218)

  • 1. The hindrances to perform the COVID-19 vaccination in Brazil.
    Boschiero MN; Palamim CVC; Marson FAL
    Hum Vaccin Immunother; 2021 Nov; 17(11):3989-4004. PubMed ID: 34353218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs.
    Moreira RDS; Costa EG; Dos Santos LFR; Miranda LHL; de Oliveira RR; Romão RF; Cozer RF; Guedes SC
    BMC Infect Dis; 2022 May; 22(1):473. PubMed ID: 35581560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
    Farias JP; da Silva PS; Fogaça MMC; Santana IVR; Luiz WB; Birbrair A; Amorim JH
    J Virol; 2022 Apr; 96(8):e0017722. PubMed ID: 35389263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Ferreira LS; de Almeida GB; Borges ME; Simon LM; Poloni S; Bagattini ÂM; da Rosa MQM; Diniz Filho JAF; Kuchenbecker RS; Camey SA; Kraenkel RA; Coutinho RM; Toscano CM
    Vaccine; 2022 Nov; 40(46):6616-6624. PubMed ID: 36210250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between SARS-CoV-2 vaccination and cases, program breakthrough cases, and deaths in Dois Vizinhos, Paraná, Brazil.
    Vasconcelos MW; de Barros FRO; Pilonetto JC; Rosa SGB; Gonçalves S; Kuhn BC; De Assis Leite DC; Perseguini JMKC; Gabiatti NC; Wendt SN; Ghisi NC
    J Med Virol; 2023 Jun; 95(6):e28882. PubMed ID: 37350013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in COVID-19 prevalence in healthcare workers in a university hospital in southern Brazil after the start of vaccination.
    Toniasso SCC; Fernandes FS; Joveleviths D; Filho FFD; Takahasi AY; Baldin CP; Pereira RM; da Silva LP; Brum MCB
    Int J Infect Dis; 2021 Aug; 109():283-285. PubMed ID: 34271203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: A retrospective observational study.
    Santos CVBD; Noronha TG; Werneck GL; Struchiner CJ; Villela DAM
    Lancet Reg Health Am; 2023 Jan; 17():100418. PubMed ID: 36575682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Siqueira PG; Duarte HO; Moura MDC
    Vaccine; 2022 Jun; 40(28):3851-3860. PubMed ID: 35610105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
    Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
    J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.